Market Research Logo

Geron Corporation (GERN) - Financial and Strategic SWOT Analysis Review

Geron Corporation (GERN) - Financial and Strategic SWOT Analysis Review

- provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

  • Business description – A detailed description of the company’s operations and business divisions.
  • Corporate strategy – Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history – Progression of key events associated with the company.
  • Major products and services – A list of major products, services and brands of the company.
  • Key competitors – A list of key competitors to the company.
  • Key employees – A list of the key executives of the company.
  • Executive biographies – A brief summary of the executives’ employment history.
  • Key operational heads – A list of personnel heading key departments/functions.
  • Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
  • Key manufacturing facilities – A list of key manufacturing facilities of the company.
  • Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights

Geron Corporation (Geron) is a clinical stage biopharmaceutical company, which undertakes the development of imetelstat, a telomerase inhibitor as first-in-class therapies for cancer. The company develops imetelstat by utilizing its proprietary nucleic acid chemistry. It is being studied for the treatment of hematological hematologic myeloid malignancies such as myelofibrosis (MF), myelodysplastic syndromes and acute myelogenous leukemia (AML). Imetelstat is also being evaluated in patients with refractory anemia with ring sideroblasts (RARS). Geron operates in partnership with Janssen Biotech, Inc., and other companies involved with oncology, diagnostics, research tools and biologics production for the development, manufacturing and commercialization of imetelstat. Geron is headquartered in Menlo Park, California, the US.

Geron Corporation Key Recent Developments

Nov 05, 2015: Geron Reports Third Quarter 2015 Financial Results
Aug 05, 2015: Geron Reports Second Quarter 2015 Financial Results
Apr 30, 2015: Geron Reports First Quarter 2015 Financial Results and Recent Events
Mar 03, 2015: Geron Reports Fourth Quarter and Annual 2014 Financial Results and Recent Events

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company


Section 1 - About the Company
Geron Corporation - Key Facts
Geron Corporation - Key Employees
Geron Corporation - Key Employee Biographies
Geron Corporation - Major Products and Services
Geron Corporation - History
Geron Corporation - Company Statement
Geron Corporation - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Joint Venture
Section 2 – Company Analysis
Geron Corporation - Business Description
Geron Corporation - Corporate Strategy
Geron Corporation - SWOT Analysis
SWOT Analysis - Overview
Geron Corporation - Strengths
Strength - Lead Product Candidate: Imetelstat
Strength - Research and Development
Strength - Patented Technology Platforms
Geron Corporation - Weaknesses
Weakness - Declining Net Working Capital
Geron Corporation - Opportunities
Opportunity - Orphan Drug Destination
Opportunity - Market Potential: Oncology
Opportunity - Demographic Trends
Geron Corporation - Threats
Threat - Stringent Government Regulations
Threat - Uncertain R&D Outcomes
Threat - Competitive Environment
Geron Corporation - Key Competitors
Section 3 – Company Financial Ratios
Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts
Section 4 – Company’s Lifesciences Financial Deals and Alliances
Geron Corporation, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016
Geron Corporation, Pharmaceuticals & Healthcare, Deals By Type, 2010 to YTD 2016
Geron Corporation, Recent Deals Summary
Section 5 – Company’s Recent Developments
Nov 05, 2015: Geron Reports Third Quarter 2015 Financial Results
Aug 05, 2015: Geron Reports Second Quarter 2015 Financial Results
Apr 30, 2015: Geron Reports First Quarter 2015 Financial Results and Recent Events
Mar 03, 2015: Geron Reports Fourth Quarter and Annual 2014 Financial Results and Recent Events
Section 6 – Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer
List of Tables
Geron Corporation, Key Facts
Geron Corporation, Key Employees
Geron Corporation, Key Employee Biographies
Geron Corporation, Major Products and Services
Geron Corporation, History
Geron Corporation, Joint Venture
Geron Corporation, Key Competitors
Geron Corporation, Ratios based on current share price
Geron Corporation, Annual Ratios
Geron Corporation, Interim Ratios
Geron Corporation, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016
Geron Corporation, Pharmaceuticals & Healthcare, Deals By Type, 2010 to YTD 2016
Geron Corporation, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios
List of Figures
Geron Corporation, Performance Chart (2011 - 2015)
Geron Corporation, Ratio Charts
Geron Corporation, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016
Geron Corporation, Pharmaceuticals & Healthcare, Deals by Type, 2010 to YTD 2016

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report